Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 324 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

NCT02478775
Conditions
Obesity, Fertility
Interventions
Degarelix (GnRH antagonist), recombinant FSH, Cetrorelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Seizure Disorder, Hypogonadism, Erectile Dysfunction
Interventions
Anastrozole 1mg, Placebo Oral Tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Malignant Female Reproductive System Neoplasm, Gynecologic Cancer, Gynecologic Neoplasm
Interventions
Physical function assessment, Self-reported Assessments and Questionnaires, Surgery (Standard of Care, Non-Interventional)
Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Completed No phase listed Observational

The Longitudinal Ovarian Reserve Study

NCT02395341
Conditions
Effects of Chemotherapy
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Radnor, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Database Studies

NCT01219296
Conditions
All Patients Undergoing Infertility Treatment
Interventions
Not listed
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2015
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving the Reproductive Health of Families

NCT03858803
Conditions
Reproductive Health
Interventions
Families Matter 2, Living as a Safer Teen
Behavioral
Lead sponsor
Portland State University
Other
Eligibility
13 Years to 80 Years
Enrollment
945 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Completed No phase listed Observational Accepts healthy volunteers

Vitamin D and Pregnancy: Camden Study

NCT02032459
Conditions
Reproductive Effects, Pregnancy
Interventions
Not listed
Lead sponsor
Rowan University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Stratford, New Jersey
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Effects of Cannabis on Male Reproductive Functions

NCT06755346
Conditions
Male Reproductive Problem
Interventions
Cannabis plant (THC 20mg), Cannabis (0%/ THC / 0% CBD), Cannabis plant (THC 40mg)
Drug
Lead sponsor
Kanako Hayashi
Other
Eligibility
21 Years to 64 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pullman, Washington
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Opiate Addiction, Pregnancy, Contraceptive Behavior, Sexual Behavior
Interventions
Nexplanon (etonogestrel contraceptive implant), Standard postpartum contraceptive care
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Advanced Lung Carcinoma, Malignant Female Reproductive System Neoplasm, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components), Questionnaire Administration
Behavioral · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Duarte, California
Conditions
Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
102
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Oakland, California + 81 more
Conditions
Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Peritoneal Carcinomatosis, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Malignant Female Reproductive System Neoplasm, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacokinetic Study
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
Interventions
KFA115, pembrolizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reproductive Hormonal Alterations in Obesity

NCT01457703
Conditions
Obesity
Interventions
Cetrorelix, Gonadorelin-GnRH, Recombinant LH, Letrozole
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Menopausal and Other Perimenopausal Disorders
Interventions
Mirena, Estradiol, Placebo Gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 52 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Not yet recruiting Not applicable Interventional

Sperm, Exposure and Endocrine Disruptors

NCT07703046
Conditions
Fertility, Male Fertility, Sperm Count, Low, Sperm Quality
Interventions
EDC Education Intervention
Behavioral
Lead sponsor
Million Marker Wellness, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Berkeley, California
Conditions
Breast Cancer, Genitourinary Cancer, Malignant Female Reproductive System Neoplasm, Melanoma, Sarcoma
Interventions
Punch Biopsy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Enrolling by invitation No phase listed Observational

Network to Understand Reproductive Rheumatology Registry

NCT06940869
Conditions
Rheumatic Diseases, Pregnancy Related, Pregnancy Interest, Reproductive Health, Autoimmune Diseases
Interventions
NURTURE Registry
Other
Lead sponsor
Duke University
Other
Eligibility
12 Years to 55 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Durham, North Carolina
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Recall by Genotype: Neuropeptide Stimulation

NCT05901467
Conditions
Reproductive Disorder
Interventions
kisspeptin 112-121, GnRH
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Infertility, Female
Interventions
Follitropin delta, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Tempe, Arizona • Encino, California • Farmington, Connecticut + 21 more
Conditions
Miscarriage, Uterus Abnormal, Infertility
Interventions
Not listed
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Conditions
Gestational Diabetes Mellitus
Interventions
STOPPING-GDM
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 20 Years · Female only
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tulsa, Oklahoma
Completed Not applicable Interventional Accepts healthy volunteers

Investigating the Regulation of Reproductive Hormones in Adult Men

NCT00392457
Conditions
Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions
ketoconazole, gonadotropin releasing hormone (GnRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts